Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Change in Inventory (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Change in Inventory for 14 consecutive years, with $467000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Change in Inventory rose 46800.0% to $467000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $732000.0, a 410.17% increase, with the full-year FY2024 number at $272000.0, up 267.9% from a year prior.
  • Change in Inventory was $467000.0 for Q2 2025 at NovaBay Pharmaceuticals, up from $355000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $565000.0 in Q1 2022 to a low of -$631000.0 in Q4 2022.
  • A 5-year average of $61000.0 and a median of $16000.0 in 2022 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: plummeted 434.75% in 2022, then skyrocketed 46800.0% in 2025.
  • NovaBay Pharmaceuticals' Change in Inventory stood at -$118000.0 in 2021, then tumbled by 434.75% to -$631000.0 in 2022, then skyrocketed by 43.42% to -$357000.0 in 2023, then soared by 199.44% to $355000.0 in 2024, then skyrocketed by 31.55% to $467000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Change in Inventory are $467000.0 (Q2 2025), $355000.0 (Q4 2024), and -$90000.0 (Q3 2024).